Clinical trial
Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory
NCT06711705 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory
- Lead sponsor
- University of California, San Diego
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 18, 2024
- Completion date
- December 31, 2030
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.